Results 151 to 160 of about 5,800 (169)

Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study

American Journal of Obstetrics and Gynecology, 2004
Paul Nyirjesy, Betsy Foxman, Jack Sobel   +2 more
exaly  

Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis

American Journal of Obstetrics and Gynecology, 1985
Jack Sobel
exaly  

Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations

American Journal of Obstetrics and Gynecology, 1998
Paul Nyirjesy, William Ledger, Betsy Foxman   +2 more
exaly  

Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India

European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009
Asad U Khan, Anis Ahmad
exaly  

Vulvovaginal candidiasis

2016
openaire   +2 more sources

Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species

Expert Opinion on Pharmacotherapy, 2018
Jack Sobel
exaly  

Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis

European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013
Rosa Mi, KRISTIAN Madeira
exaly  

Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms

American Journal of Obstetrics and Gynecology, 2019
Alexander Tertychnyy, Alexander Guschin, Hans Verstraelen   +2 more
exaly  

Lactobacillus helveticus HY7801 ameliorates vulvovaginal candidiasis in mice by inhibiting fungal growth and NF-κB activation

International Immunopharmacology, 2012
Kyung-Ah Kim, Myung Joo Han, Chul Sung Huh   +2 more
exaly  

Assessment of in vitro biofilm formation by Candida species isolates from vulvovaginal candidiasis and ultrastructural characteristics

Micron, 2012
Marcia Edilaine Lopes Consolaro, Lucélia Donatti, Terezinha Svidzinski   +2 more
exaly